Abstract:RNA interference (RNAi) provides researchers with a versatile means to modulate target gene expression. The major forms of RNAi molecules, genome-derived microRNAs (miRNAs) and exogenous small interfering RNAs (siRNAs), converge into RNA-induced silencing complexes to achieve posttranscriptional gene regulation. RNAi has proven to be an adaptable and powerful therapeutic strategy where advancements in chemistry and pharmaceutics continue to bring RNAi-based drugs into the clinic. With four siRNA medications already approved by the US Food and Drug Administration (FDA), several RNAi-based therapeutics continue to advance to clinical trials with functions that closely resemble their endogenous counterparts. Although intended to enhance stability and improve efficacy, chemical modifications may increase risk of off-target effects by altering RNA structure, folding, and biologic activity away from their natural equivalents. Novel technologies in development today seek to use intact cells to yield true biologic RNAi agents that better represent the structures, stabilities, activities, and safety profiles of natural RNA molecules. In this review, we provide an examination of the mechanisms of action of endogenous miRNAs and exogenous siRNAs, the physiologic and pharmacokinetic barriers to therapeutic RNA delivery, and a summary of the chemical modifications and delivery platforms in use. We overview the pharmacology of the four FDA-approved siRNA medications (patisiran, givosiran, lumasiran, and inclisiran) as well as five siRNAs and several miRNA-based therapeutics currently in clinical trials. Furthermore, we discuss the direct expression and stable carrier-based, in vivo production of novel biologic RNAi agents for research and development. SIGNIFICANCE STATEMENT In our review, we summarize the major concepts of RNA interference (RNAi), molecular mechanisms, and current state and challenges of RNAi drug development. We focus our discussion on the pharmacology of US Food and Drug Administration-approved RNAi medications and those siRNAs and miRNA-based therapeutics that entered the clinical investigations. Novel approaches to producing new true biological RNAi molecules for research and development are highlighted.

Subcellular Fate and Off-Target Effects of siRNA, shRNA, and miRNA

siRNA Specificity: RNAi Mechanisms and Strategies to Reduce Off-Target Effects

Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application

A comprehensive update of siRNA delivery design strategies for targeted and effective gene silencing in gene therapy and other applications

Rna Interference: A Potent Tool for Gene-Specific Therapeutics

Therapeutic Potentials of Gene Silencing by RNA Interference: Principles, Challenges, and New Strategies.

siRNA, miRNA, and shRNA: in vivo Applications

Chemical Modification and Delivery System of Small Interfering RNA Drugs

Advances of Non-specific Effects on RNAi

Engineering siRNA therapeutics: challenges and strategies

RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies

siRNA vs. shRNA: Similarities and differences

Small interfering RNA for experimental cancer therapy.

RNA Interference and Potential Applications

Research Progress on Sirna Delivery with Nonviral Carriers

Synthetic SiRNA Delivery: Progress and Prospects

Research progress on siRNA delivery with nonviral carriers.

RNA Interference-Based Cancer Drugs: The Roadblocks, and the "Delivery" of the Promise

Progress on RNAi-based molecular medicines.

Research Advances of siRNA-Based Molecular Medicines

Biomaterials in siRNA Delivery: A Comprehensive Review.